Lupin Ltd has named Abdelaziz Toumi as the Chief Executive Officer (CEO) of Lupin Manufacturing Solutions (LMS), their new subsidiary.

LMS is involved in developing, manufacturing, and selling active pharmaceutical ingredients (APIs) and is beginning to set up its contract development and manufacturing operations (CDMO) business.

Toumi’s appointment is effective from June 17, 2024. However, the duration of his tenure is not fixed, as revealed by Lupin via a press release. He has more than 20 years of experience in the biotech, pharma, and CDMO sectors, and has worked in Europe, North America, and Asia. He holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.

Previously, Toumi has worked as the Chief Business Officer of KBI Biopharma, as the Vice President and Head of mRNA Business & New Ventures at Catalent Pharma Solutions, and has also held significant positions in companies like Merck Group and Bayer Technology Services.

Also Read | Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

Lupin, a transnational pharmaceutical company led by innovation, deals with the development and commercialisation of branded and generic formulations, biotechnology products, and APIs in more than 100 markets. Their presence is spread across the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!